Become A Featured Company

New Independent Study Correlates THC in Breath and Blood using Cannabix Technology

Ryan Allway

May 16th, 2022

News, Top Story

The legalization of cannabis promises to solve many of society’s problems and unlock new economic opportunities. However, the move also creates new challenges for law enforcement. For instance, studies suggest that cannabis may acutely impair several driving-related skills in a dose-related fashion, but there’s no easy roadside test available.

Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) aims to solve that problem with novel marijuana breathalyzer tools for law enforcement and workplaces. A new independent study showed an excellent correlation between breath samples collected and analyzed with its proprietary hardware and blood plasma levels of ∆9-tetrahydrocannabinol (“THC”) .

Reading blood levels is currently the standard measurement for law enforcement, toxicologists and evidence used in courts of law, therefore it is important to correlate new methods of drug screening to blood levels. Let’s take a closer look at the study, and what’s in store for the future.

Study

Dr. Phillip Olla of Audacia Bioscience in Ontario conducted a study on six subjects with an average age of 23 years. Breath and blood samples were taken simultaneously at the baseline (before smoking cannabis) and at incremental time points (after smoking cannabis) out to one hour and 40 minutes after smoking activity was complete.

The results showed an excellent correlation between human breath samples collected and analyzed with the Cannabix hardware and blood plasma levels of THC. Furthermore, the data from the study support literature by showing the same trends in THC metabolism, and that blood and breath levels of THC over time correlate with high accuracy.

“This study shows the capability of the Cannabix Breath Analysis system to easily and rapidly collect breath samples in the field and correlate to blood THC levels,” said Cannabix Sr. Analytical Chemist, Dr. Jared Boock. “Law enforcement and toxicologists rely on gold standard mass spectrometry results to confirm drug presence in blood. We have developed a truly ground-breaking breath analysis tool capable of breath sampling for THC, within seconds, with no sample preparation needed. Furthermore, we were able to store, ship and analyze samples for up to 40 hours after they were taken in the field.”

Why Breath Matters

Alcohol breathalyzers became widely available to law enforcement and employers in the 1960s. The technology measures alcohol content by creating a chemical reaction that oxidizes the alcohol in a breath sample and produces an electrical current. And the current determines the subject’s blood alcohol content or BAC.

Unfortunately, marijuana breathalyzers are presented a much harder challenge. THC that appears in breath samples is typically measured in picograms (trillionths of a gram), meaning any breathalyzer would have to be extremely sensitive. As a result, law enforcement and employers have relied on intrusive blood or urine samples to detect intoxication as new breath testing technology has been in the intense research and development phase.

Cannabix leverages its unique sample collection and hardware to detect these low concentrations in an accurate and selective manner. Consequently, the laboratory device is capable of breath sampling for THC within seconds with no sample preparation, and breath samples can be stored and analyzed up to 40 hours after being taken. This important laboratory technique and independent study results are a precursor to its portable capabilities that are under development and maturing quickly.

Looking Ahead

Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) has made substantial progress in developing its marijuana breathalyzer technology is quickly developing technology that could be used in industry and law enforcement to overcome major economic (link to https://www.politico.com/news/2022/05/07/cannabis-truckers-supply-chain-woes-00030508 ) and public safety challenges facing the US and world.

For more information, visit the company’s website or download their investor presentation.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading